Allopurinol for chronic gout

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Seth, Rakhi ^a   Kydd, Alison S R ^b   Buchbinder, Rachelle ^c   Bombardier, Claire ^d   Edwards, Christopher J ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MONASH UNIVERSITY   (Australia)

^d INSTITUTE FOR WORK AND HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE; FEBUXOSTAT; PEGLOTICASE; PLACEBO; PROBENECID; RASBURICASE; SULFINPYRAZONE; URATE;

ARTHRALGIA; ARTICLE; CHRONIC GOUT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GOUT; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL;

EID: 85041531180     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006077.pub2     Document Type: Article

References (21)

1. Busquets N, Carmona L, Suris X. Systematic review: safety and efficacy of anti-TNF in elderly patients.. Rheumatologica Clinica 2011;7(2):104-12.
2. Cates C. Visual Rx. 3. Dr Christopher Cates, 2008.
3. Chohan S, Becker MA. Update on emerging urate lowering therapies. Current Opinion in Rheumatology 2009;21(2):143-9. [PUBMED: P].
4. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: Walking the tightrope between adequate urate lowering and adverse events. Seminars in Dialysis September-October 2007;20(5):391-5.
5. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
6. Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J, et al.Sex differences in gout epidemiology:evaluation and treatment. Annals of the Rheumatic Diseases 2006;65(10):1368-72.
7. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
8. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
9. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
10. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007;46(8):1372-4.
11. Klippel JH, Dieppe PA, Brooks P, Carette S, Dequeker J, Gerber LH, et al.Rheumatology. Mosby, 1994.
12. The Cochrane Collaboration. RevMan. Version 5.1. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2011.
13. Schlesinger N. Management of acute and chronic gouty arthritis. Drugs 2004;64(21):2399-416.
14. Schumacher HR, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst D, et al.OMERACT 7 Special Interest Group on Outcome Measures for Acute and Chronic Gout. OMERACT proceedings. 2005.
15. Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, et al.Outcomes domains for studies of acute and chronic gout. Journal of Rheumatology 2009;36(10):2342-5.
16. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
17. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
18. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
19. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis and Rheumatism 1977;20:895-900.
20. Wallace SL, Singer JZ. Therapy in gout. Rheumatic Diseases Clinics of North America 1988;14(2):441-57.
21. Wortmann RL. Gout and hyperuricaemia. Current Opinion in Rheumatology 2002;14(3):281-6.